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Abstract
Background: HIV-1 in genital secretions may be opsonized by several molecules including complement components. 
Opsonized HIV-1 by complement enhances the infection of various mucosal target cells, such as dendritic cells (DC) 
and epithelial cells.
Results: We herein evaluated the effect of HIV-1 complement opsonization on microbicide candidates' activity, by 
using three in vitro mucosal models: CCR5-tropic HIV-1JR-CSF transcytosis through epithelial cells, HIV-1JR-CSF attachment 
on immature monocyte-derived dendritic cells (iMDDC), and infectivity of iMDDC by CCR5-tropic HIV-1BaL and CXCR4-
tropic HIV-1NDK. A panel of 10 microbicide candidates [T20, CADA, lectines HHA & GNA, PVAS, human lactoferrin, and 
monoclonal antibodies IgG1B12, 12G5, 2G12 and 2F5], were investigated using cell-free unopsonized or opsonized 
HIV-1 by complements. Only HHA and PVAS were able to inhibit HIV trancytosis. Upon opsonization, transcytosis was 
affected only by HHA, HIV-1 adsorption on iMDDC by four molecules (lactoferrin, IgG1B12, IgG2G5, IgG2G12), and 
replication in iMDDC of HIV-1BaL by five molecules (lactoferrin, CADA, T20, IgG1B12, IgG2F5) and of HIV-1NDK by two 
molecules (lactoferrin, IgG12G5).
Conclusion: These observations demonstrate that HIV-1 opsonization by complements may modulate in vitro the 
efficiency of candidate microbicides to inhibit HIV-1 infection of mucosal target cells, as well as its crossing through 
mucosa.
Background
Recent disappointing failure in microbicide clinical trials
revealed that major gaps in basic and applied knowledges
remain to conceive effective microbicide formulations [1-
3]. In particular, the failure of phase II/III essays on candi-
date molecules having crossed successfully all the previ-
ous stages of the preclinical development, emphasizes the
absolute necessity to establish a correlation between the
preclinical criteria and the clinical criteria of microbicide
molecules development [3]. Thus, one of the major objec-
tives of in vitro evaluation of microbicide candidate mole-
cules during their preclinical development is to get closer
as much as possible to physiological conditions.
The inhibitory power of microbicide molecules may be
affected by semen factors when male and female genital
secretions are mixed during sexual intercourse, including
pH, mucosal antibodies [4] and humoral soluble factors
[5,6] For example, it has been recently demonstrated that
the in vitro efficacy of polymeric microbicide molecules,
acting as HIV-1 entry inhibitors, might become at least
partly compromised by the presence of seminal plasma
[7].
The system of the complement constitutes one of the
first lines of innate defence. Its interaction with a multi-
tude of pathogenic agents like viruses, leads its activation
in cascade which ends in the deposit of C3 fragments on
their surface. Unlike other pathogenic agents, the major-
ity of HIV-1 particles escape the lysis by complement [8].
Free HIV-1 particles present in genital secretions may be
likely opsonized by semen complement components [9-
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inal fluid [9,11], and HIV by it-self is known to strongly
activate the complement system [10]. We previously
showed that opsonization of HIV-1 with complement
enhanced infection of epithelial cells [12], and also
enhanced infection of dendritic cells and viral transfer to
CD4 T cells in a CR3 and DC-SIGN-dependent manner
[13]. Thus, these findings support the hypothesis that the
activity of microbicide molecules against HIV-1 may be
influenced by the opsonization of the virus.
The aim of the present proof-of-concept study was to
evaluate whether complement opsonization may affect
the in vitro activity of a panel of microbicide molecule
candidates acting against early steps of HIV-1 infection.
Materials and methods
Virus strains
Primary CCR5-tropic HIV-1JR-CSF and CXCR4-tropic
HIV-1NDK were a gift from F. Barré-Sinoussi (Institut Pas-
teur, Paris). CCR5-tropic HIV-1BaL was provided by the
National Institutes of Health (NIH, Maryland, USA). The
viral stocks were amplified in monocyte-derived mac-
rophages (MDM) of healthy donors and quantified by p24
capture ELISA measurements (DuPont de Nemours,
France).
Cells
Peripheral blood mononuclear cells (PBMC) were iso-
lated from buffy coats of healthy adult donors by Ficoll
density gradient centrifugation on Medium for Separa-
tion of Lymphocytes (MSL, Eurobio, Les Ulis, France), as
previously described [14]. The percentage of monocytes
was determined by flow cytometry using forward scatter
and side scatter properties (FSC/SSC). PBMC were re-
suspended in RPMI-1640 medium supplemented with L-
glutamine, penicillin (100 IU/ml) and streptomycin (100
μg/ml). Cells were seeded into 24 well-plates (Costar,
Cambridge, MA) at 106 adherent cells/ml, and incubated
at 37°C for 45 min. Non-adherent cells were removed by 4
washes. Adherent monocytes were incubated in RPMI-
1640 medium with 10% fetal calf serum (FCS), L-glu-
tamine, and antibiotics. The relative concentration of
rhM-CSF improved cell viability and maintained a neu-
tral environment with respect to activation marker quan-
titative expression (HLA-DR, CD14, CD16), which
remained similar to that of MDM cultured in medium
alone. Immature monocyte-derived dendritic cells
(iMDDC) were generated from monocytes in the pres-
ence of rhGM-CSF (10 ng/ml) in combination with rh-IL-
4 (10 ng/ml). The medium, including all supplements,
was replaced the third day of differentiation. After 6 days
of culture, adherent cells corresponding to the dendritic
cell-enriched fraction were harvested, washed, and used
for subsequent experiments. Flow cytometry analysis
(Becton Dickinson, NJ, USA) demonstrated that the den-
dritic cells were more than 90% pure.
The epithelial endometrial cell line HEC-1A was from
the American Type Culture Collection [15], and was
maintained in RPMI-1640 containing 10% FCS and anti-
biotics (100 μg of streptomycin per ml, and 100 IU of
penicillin per ml).
Candidate molecules
The gp120-interacting plant lectins Hippeastrum hybrid
(amaryllis) (HHA) and Galanthus nivalis (snowdrop)
(GNA) were derived and purified from the bulbs of these
plants, as previously described [16]. The gp120-interact-
ing sulfated polyvinyl alcohol (PVAS) which inhibits the
virus entry, (molecular weight, 20,000 Da) was synthe-
sized in the form of its sodium salts by the sulfation of
PVA (polyvinyl alcohol) with chlorosulfonic acid in pyri-
dine-dimethylformamide solution [17]. Human lactofer-
rin (Lf ) [18] which limits the HIV-1 attachment on
dendritic cells by inhibiting virus attachment on heparan
sulfate proteoglycans [14] and mannan were obtained
from Sigma-Aldrich (Saint-Louis, MO). CADA (cyclotri-
azadisulfonamide) [19] which inhibits the HIV entry by
CD4 receptor down-modulating, was supplied by T.W.
Bell (University of Nevada, Reno, NV) via the European
Microbicides Project (EMPRO). The HIV-1 fusion inhibi-
tor enfuvirtide (T20) and the HIV-1-specific neutraliza-
tion monoclonal antibodies, IgG 2F5 directed to HIV-1
gp41, IgG 2G12 directed to HIV-1 carbohydrate side-
chains of gp120, IgG 1B12 directed to the CD4 binding
site of HIV-1 gp120 as well as IgG 12G5 directed to HIV-
1 CXCR4 co-receptor, were obtained through the AIDS
Reagent Program, Division of AIDS, NIAID, NIH.
Different concentrations of molecules dissolved in
RPMI-1640 were used: Lectines HHA and GNA (1, 10
and 100 μg/ml), Lf (200 μg/ml), PVAS (1, 10 and 100 μg/
ml), CADA (0.2 and 2 μg/ml), T20 (0.5 and 5 μg/ml),
IgG2G12 (1 and 10 μg/ml), IgG2F5 (7.5 and 25 μg/ml),
IgG12G5 (2.5 and 12.5 μg/ml), and IgG1B12 (1 and 10 μg/
ml) and polyclonal anti-gp160 antibodies (10 μg/ml) as
positive control for HIV inhibition.
Complement opsonization of HIV-1
The activation of complement by HIV-1 and the genera-
tion of C3a Ag were similar by using a vol/vol ratio of
human serum or seminal fluid, as previously demon-
strated [12]. Thus, in our experimentations, human
serum obtained from HIV-1-seronegative individuals was
used as source of complement. Activation of serum com-
plement and opsonization of free virus particles were car-
ried out, as previously described [20]. Briefly, free HIV-1
(1 to 5 ng of HIV-1 p24 antigen) were added in a vol/vol
ratio to serum supplemented with 0.6 mM CaCl2 and 0.9
mM MgCl2 for 1 h at 37°C in order to initialize the com-
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controls, serum was heat-inactivated by incubation for 1
h at 56°C, and added to viral particles in similar condi-
tions to obtain heat-inactivated non-opsonized free HIV-
1 (HI NonOps). Negative control corresponding to non-
opsonized HIV-1 (NonOps) was obtained by HIV-1 incu-
bation in culture medium for 1 h at 37°C.
Inhibition of HIV-1 transcytosis
HEC-1A cells were grown on a 0.4 μm-pore polycarbon-
ate permeable support (Transwell, Costar, MA), as previ-
ously described [21]. Tightness of the monolayer of HEC-
1A cells was monitored by measuring resistance at day 6
of culture that must have reached 300 Ω/cm2. Increasing
concentrations of microbicide molecules and HIV-1 (5 ng
of HIV-1 p24 antigen) pre-incubated with complement or
heat-inactivated complement were then added to the api-
cal side of HEC-1A for 3h at 37°C. HIV-1 transcytosis was
assessed by measuring the p24 antigen concentration in
the basolateral chamber medium by p24 antigen capture
ELISA. Positive control for transcytosis consisted of free
HIV-1. Positive control for transcytosis inhibition con-
sisted of free HIV-1 incubated 30 min with purified poly-
clonal antibodies directed to HIV-1 gp160 before to be
added to the apical side of the HEC-1A cell cultures, as
described [21].
Inhibition of HIV-1 adsorption on dendritic cells
Complement-Ops or NonOps HIV-1 (1 ng of HIV-1 p24
antigen) were incubated with iMDDC (105 cells/well) in
the presence of increasing concentrations of microbicide
molecules for 1 h at 37°C. After 4 washes to remove unat-
tached virus, cells were lysed by adding PBS 1% Triton X-
100 for 45 min at 37°C, and the concentration of HIV-1
p24 antigen was measured [14]. Polyclonal purified anti-
bodies to gp160 and mannan were used as positive con-
trols.
Inhibition of iMDDC infection by HIV-1
Cells were washed 2 times after 6 days of differentiation
and seeded into 96-well culture plates (5 × 105 cells per
well). Complement-Ops or NonOps HIV-1 (1 ng p24
antigen/ml) and increasing concentrations of microbicide
candidate molecules were added on cells and incubated
for 3 h at 37°C in a 5% CO2 atmosphere. Each sample was
performed in triplicate. After 4 washes to remove exceed-
ing virus, cells were cultured for 3 days. The amounts of
virus replication were monitored by HIV-1 p24 antigen
ELISA. In this last case, supernatants were harvested and
virus particles were lysed by incubation for 45 min at
37°C with 1% Triton X-100. Polyclonal purified antibod-
ies to gp160 were used as positive controls.
Statistical analysis
Mann-Whitney U-test was used for statistical analysis,
with P < 0.05 being considered as significant.
Results
HIV-1 transcytosis inhibition by microbicide candidate 
molecules upon HIV-1 complement opsonization
HIV-1JR-CSF was incubated with increasing compound
concentrations before to be added to the apical mem-
brane of HEC-1A cells. As shown in Table 1, the transcy-
tosis of NonOps HIV-1 and that of HI NonOps HIV-1
were inhibited in a dose-dependent manner by HHA. In
contrast, HHA had no effect on transcytosis of Ops HIV-
1. Thus, HHA lost its ability to block HIV-1 transcytosis
when the virus was opsonized by complement compo-
nents. PVAS inhibited transcytosis of Ops HIV-1, HI
NonOps HIV-1 and NonOps HIV-1. For a given concen-
tration, PVAS inhibited with the same efficiency the tran-
scytosis of Ops HIV-1 and that of NonOps HIV-1. The
other microbicide candidates did not interfere with the
transcytosis of Ops HIV-1, HI NonOps HIV-1, and Non-
Ops HIV-1. As positive control for HIV-1 transcytosis
inhibition, polyclonal anti-gp160 antibodies (10 μg/ml)
inhibited at 90% the transcytosis of Ops HIV-1, HI Non-
Ops HIV-1 and NonOps HIV-1. Free Ops HIV-1, HI
NonOps HIV-1 and NonOps HIV-1, not incubated with
microbicide molecules nor with anti-gp160 antibodies,
were capable to be transcytosed through HEC-1 cells
with identical rates. Similar results were obtained when
Ops HIV-1, HI NonOps HIV-1 and NonOps HIV-1 were
incubated with irrelevant immunoglobulins (not shown).
In summary, upon complement opsonization, transcyto-
sis blocking was abolished for 1 molecule (HHA).
Inhibition of HIV-1 adsorption on iMDDC by the 
microbicide molecules upon HIV-1 complement 
opsonization
HHA and GNA lectins at concentrations of 100 μg/ml
inhibited the adsorption of Ops HIV-1, NonOps HIV-1
and HI NonOps HIV-1 on iMDDC with similar efficien-
cies (Table 2). Lf and the monoclonal antibodies
IgG1B12, IgG12G5, and IgG2F5 showed differential
effect on the inhibition of HIV-1 adsorption on iMDDC
according to complement opsonization of the virus.
Thus, they had no effect on Ops HIV-1 attachment to
iMDDC, whereas they inhibited the attachment of Non-
Ops HIV-1 as well as HI NonOps HIV-1. PVAS, CADA
and T20 did not interfere with the attachment of Ops and
NonOps HIV-1 on iMDDC. Both positive controls, poly-
clonal antibodies to gp160 (10 μg/ml) and mannan (250
μg/ml), inhibited the adsorption of NonOps and HI Non-
Ops HIV-1, but their inhibiting capacities decreased for
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opsonization, HIV-1 adsorption on iMDDC was counter-
acted by four molecules (Lf, IgG1B12, IgG2G5,
IgG2G12).
HIV-1 replication in iMDDC by the microbicide molecules 
upon HIV-1 complement opsonization
The molecules Lf, CADA, T20, IgG1B12, IgG2G12 and
IgG2F5 inhibited the iMDDC infection by NonOps HIV-
1BaL in a dose-dependent manner (Table 3). These latter
molecules were able to inhibit the Ops HIV-1BaL, but
their inhibiting capacity was decreased, except for
IgG2G12 which inhibited both Ops and NonOps HIV-1
to a similar extent. IgG12G5 did not have any effect when
the cells were infected by HIV-1BaL. The molecules Lf,
Table 1: Inhibition by microbicide molecule candidates of the 
transcytosis of HIV-1JR-CSF through a tight monolayer of 
endometrial epithelial HEC-1A cells
NonOps HI NonOps Ops
HHA I (54%)* I (48%) NI [S]**
GNA NI NI NI
PVAS I (65%) I (63%) I (65%)
Lf NI NI NI
CADA NI NI NI
T20 NI NI NI
IgG1B12 NI NI NI
IgG12G5 NI NI NI
IgG2G12 NI NI NI
IgG2F5 NI NI NI
Ab to gp160*** I (90%) I (90%) I (90%)
* Percentage of transcytosis inhibition in brackets
** Significant difference between the percentages of transcytosis 
inhibition according to Ops, HI NonOps and NonOps HIV-1 (Mann & 
Whitney U test)
*** Used as positive control
NonOps: Non opsonized free HIV-1; HI NonOps: Heat inactivated non 
opsonized free HIV-1; Ops: Free HIV-1 opsonized virus by 
complement components
I: Transcytosis inhibition; NI: Lack of transcytosis inhibition
S: Significant
The transcytosis inhibition is shown for the best doses of the 
candidate molecules, and is expressed as percentage of the average 
of three independent experiments. The range of detected HIV-1 p24 
antigen for uninhibited transcytosis in negative control 
experimentation (without microbicide molecules) was 150-210 pg/
ml.
Table 2: Inhibition of the adsorption of HIV-1JR-CSF on immature 
monocyte-derived dendritic cells by microbicide molecule 
candidates
NonOps HI NonOps Ops
HHA I (47%)* I (43%) I (48%)
GNA I (47%) I (43%) I (48%)
PVAS NI NI NI
Lf I (37%) I (32%) NI [S]**
CADA NI NI NI
T20 NI NI NI
IgG1B12 I (28%) I (14%) NI [S]
IgG12G5 I (26%) I (16%) NI [S]
IgG2G12 I (19%) I (16%) NI [S]
IgG2F5 I (17%) I (17%) I (11%)
Mannan*** I (42%) I (33%) NI [S]
Ab to gp160*** I (52%) I (47%) I (21%) [S]
* Percentage of inhibition of virus adsorption on dendritic cells in 
brackets
** Significant difference between the percentages of adsorption 
inhibition according to Ops, HI NonOps and NonOps HIV-1 (Mann & 
Whitney U test)
*** Used as positive controls
NonOps: Non opsonized free HIV-1; HI NonOps: Heat inactivated non 
opsonized free HIV-1; Ops: Free HIV-1 opsonized virus by 
complement components
I: Inhibition of virus adsorption on dendritic cells; NI: Lack of 
inhibition of virus adsorption on dendritic cells
S: Significant
The adsorption inhibition is shown for the optimal doses of the 
candidate molecules, and is expressed as percentage of the average 
of three independent experiments. The range of detected HIV-1 p24 
antigen for uninhibited adsorption in negative control 
experimentation (without microbicide molecules) was 200-500 pg/
ml. The capability of dendritic cells to capture HIV is donor-
dependent.
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ited the replication of NonOps HIV-1NDK in iMDDC in a
dose-dependent manner. Similarly, they were able to
inhibit Ops HIV-1 without reduction in their inhibitory
capacities, except Lf and IgG12G5. The polyclonal anti-
bodies to gp160, used as positive control, inhibited the
infection of dendritic cells by Ops, HI NonOps and Non-
Ops HIV-1BaL or HIV-1NDK, at 50-61% and 69-91%,
respectively (Table 3). In summary, upon complement
opsonization, replication of HIV-1BaL in iMDDC was
changed for 5 molecules (Lf, CADA, T20, IgG1B12,
IgG2F5) and that of HIV-1NDK for 2 molecules (Lf,
IgG12G5).
Discussion
The present proof-of-concept study was conceived to
evaluate the influence of HIV-1 opsonization by comple-
ment components on the inhibition of HIV-1 transcytosis
through a monolayer of human endometrial epithelial
cells, HIV-1 capture by dendritic cells, and HIV-1 pro-
ductive infection of dendritic cells by a panel of 10 micro-
bicide candidate molecules. Upon complement
opsonization, transcytosis blocking was changed by 1
molecule (HHA), HIV-1 adsorption on iMDDC for 4
molecules (Lf, IgG1B12, IgG2G5, IgG2G12), and replica-
tion in iMDDC of HIV-1BaL by 5 molecules (Lf, CADA,
T20, IgG1B12, IgG2F5) and of HIV-1NDK by 2 molecules
(Lf, IgG12G5). These findings clearly demonstrate that
HIV-1 opsonization by complement components may
modulate in vitro the efficiency of microbicide candidate
molecules to inhibit HIV-1 infection of potential mucosal
target cells, as well as the crossing of the virus through
mucosa. Since complement is present in male genital
fluid, these observations allow to make the hypothesis
Table 3: Inhibition of the production of HIV-1BaL or HIV-1NDK in immature monocyte-derived dendritic cells by microbicide 
molecule candidates
HIV-1BaL HIV-1NDK
NonOps HI NonOps Ops NonOps HI NonOps Ops
Lf I (30%)* I (26%) NI [S]** I (63%) I (61%) I (26%) [S]
CADA I (61%) I (64%) NI [S] I (95%) I (93%) I (96%)
T20 I (83%) I (82%) I (57%) [S] I (95%) I (95%) I (97%)
IgG1B12 I (86%) I (85%) I (60%) [S] I (94%) I (96%) I (94%)
IgG12G5 NI NI NI I (95%) I (95%) I (54%) [S]
IgG2G12 I (67%) I (62%) I (69%) I (96%) I (95%) I (96%)
IgG2F5 I (84%) I (77%) I (41%) [S] I (97%) I (96%) I (97%)
Ab to 
gp160***
I (61%) I (58%) I (50%) [S] I (79%) I (91%) I (69%)
* Percentage of virus production inhibition in brackets
** Significant difference between the percentages of production inhibition is significant according to Ops, HI NonOps and NonOps HIV-1 
(Mann & Whitney U test)
*** Used as positive control
NonOps: Non opsonized free HIV-1; HI NonOps: Heat inactivated non opsonized free HIV-1; Ops: Free HIV-1 opsonized virus by complement 
components
I: Virus production inhibition; NI: Lack of transcytosis inhibition
S: Significant
The infection inhibition is shown for the best doses of the candidate molecules, and is expressed as percentage of the average of three 
independent experiments. The range of detected HIV-1 p24 antigen for uninhibited HIV-1 replication in negative control experimentations 
(without microbicide molecules) was 800-1000 pg/ml in iMDDC infectivity assay. The capability of dendritic cells to replicate HIV-1 is donor-
dependent.
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modulate in vivo the anti-HIV-1 activity of microbicides.
Among several factors possibly involved in the modula-
tion of microbicide activity by seminal plasma, we
focused on complement components. Indeed, comple-
ment components have been detected in all body secre-
tions, including seminal fluid [9,11]. Since HIV is known
to activate complement system [10], HIV-1 particles in
male genital secretions may be likely opsonized by semen
components. Activation of complement by HIV-1 results
in deposition of C3 fragments on the viral surface with-
out formation of complement lysis complex [22,23],
resulting in opsonized HIV-1 harboring complement
components covalently linked to the surface viral glyco-
proteins, and thus changing the virus phenotype [8,22,24-
29]. In addition, opsonization of HIV-1 with complement
modulates in vitro the infection of epithelial [12] and den-
dritic cells[13], as well as the transfer of HIV-1 from den-
dritic cells to CD4 T cells [13].
We first evaluated the ability of each molecule to inhibit
HIV-1 transcytosis through a monolayer of epithelial cells
[21,30] in the presence or absence of HIV-1 opsonization
by complement. The HIV-1JR-CSF strain was exclusively
used in our transcytosis assays, because transcytosis was
shown to be selective, the HIV-1BaL. strain being not able
to cross the monolayer of HEC1 epithelial cells [21]. Both
free NonOps and Ops HIV-1 were similarly transcytosed.
HHA and PVAS molecules limited efficiently NonOps
HIV-1 transcytosis. Incubation of Ops HIV-1 with HHA
or PVAS resulted in a complete loss of the ability of HHA
to block transcytosis, whereas PVAS remained efficient.
Indeed, the mannose-specific lectin HHA may inhibit
HIV-1 entry into its target cells by interacting with the
heavily glycosylated gp120 envelope glycoprotein
[16,31,32]. In parallel, high-mannose-binding comple-
ment fragments interact with gp120 [4]. Thus, HHA-
binding sites on gp120 may be hidden by complement
molecules when the virus is opsonized. In contrast to
HHA, GNA did not interfere with NonOps and Ops HIV-
1 transcytosis. GNA has predominant specificity for α(1-
3)-linked mannose residues whereas HHA can recognize
both α(1-3)- and α(1-6)-linked mannose residues [27].
The differential effect observed for these two lectins in
association with the lack of HIV-1 transcytosis inhibition
by HHA when the virus is opsonized, suggests that free
α(1-6)-linked mannose residues are no more accessible at
the surface of complement opsonized virus. PVAS inhib-
ited HIV-1 transcytosis independently of the virus
opsonization. PVAS is a polyanionic molecule that may
exert its activity against HIV-1 by shielding-off the posi-
tively charged aminoacid residues on the V3/gp120 loop
[17], thus preventing the interaction of gp120 with hepa-
ran sulfated proteoglycans (HSPG) which are largely
expressed on epithelial cells and involved in HIV-1
adsorption [33,34]. Complement opsonization of HIV-1
was not able to prevent PVAS inhibitory activity, suggest-
ing that opsonization does not modify the positively
charged HIV-1 surface glycoproteins and that the PVAS
target site on gp120 could be reachable even in the pres-
ence of complement components.
We further investigated whether opsonization of HIV-1
may modulate the capability of microbicide molecules to
inhibit HIV-1 adsorption on dendritic cells. HIV-1
opsonization enhanced by 50% viral adsorption on den-
dritic cells as compared with NonOps HIV-1, as previ-
ously reported [13]. Such increased binding of HIV-1
could be explained by the expression on dendritic cells of
complement receptors (CR3). Increased binding of HIV-1
could facilitate the infection of dendritic cells since com-
plement is considered as an enhancer of HIV-1 infection
[12,13,20,22,23,25]. HHA and GNA inhibited with the
same efficiency NonOps and Ops HIV-1 adsorption.
PVAS, which hampers the interaction between HIV-1
and HSPG expressed on target cells, had no effect on
HIV-1 adsorption on dendritic cells, likely because these
cells express only slightly HSPG. Since plant lectins do
not interfere with DC-SIGN [36], a mannose receptor
largely expressed on dendritic cells [32], our observations
suggest that other mannose receptors than DC-SIGN
may be involved in HIV-1 adsorption on dendritic cells,
as previously reported [37,38]. One hypothesis could be
that NonOps and Ops HIV-1 interact principally with
surface proteins exhibiting terminal α(1-3)-mannosyla-
tion on dendritic cells. In contrast, PVAS had no effect on
HIV-1 adsorption on dendritic cells. Mannan, a major
mannose binding proteins ligand, inhibited adsorption of
NonOps virus, but was less effective by using the Ops
HIV-1. This phenomenon confirms then that NonOps
and Ops viruses may use different receptors involved in
their adsorption at the surface of dendritic cells, as previ-
ously reported [13].
The HIV-1-specific monoclonal antibodies were able to
inhibit the NonOps HIV-1, but not Ops HIV-1. The virus
opsonized by complement fragments uses the comple-
ment receptor type 3 (CR3) for its adsorption on den-
dritic cells [13]. Thus, the viral glycoproteins gp41 and
gp120 are likely less used for virus adsorption on den-
dritic cells in presence of complement compounds, as
strongly suggested by the less efficiency of polyclonal
antibodies to gp160 to inhibit the adsorption of Ops HIV-
1 at the surface of dendritic cells. Lf was no more able to
inhibit HIV-1 adsorption on dendritic cells when the
virus was opsonized. This latter finding suggests the exis-
tence of a Lf-binding site hidden by complement compo-
nents. Lf may prevent NonOps HIV-1 adsorption on
dendritic cells by cell receptors not used by Ops HIV-1,
like nucleolin involved in the adsorption on the cellular
membrane of both Lf and HIV-1 [39,40]. Taken together,
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tion of HIV-1 in human genital secretions may allow the
virus to escape to the antiviral activity of natural inhibi-
tors such as Lf.
Finally, we evaluated the role of opsonization on den-
dritic cell infection. The monoclonal antibody IgG12G5,
an inhibitor of CXCR4 coreceptor, had no effect on the
replication of CCR5-tropic HIV-1. All tested molecules
inhibited the infection of dendritic cells by CCR5- and
CXCR4- tropic NonOps HIV-1. By using the CCR5-
tropic Ops HIV-1BaL, we observed that the inhibitory
effects of the microbicide candidates significantly
decreased in the presence of the complement. In con-
trast, the molecules inhibited the CXCR4-tropic Ops
HIV-1NDK with the same efficiency as the NonOps HIV-
1NDK, except for Lf and IgG 12G5. According to the
hypothesis proposed by Margolis & Shattock [41], the
CCR5-tropic viral strains may be selected during the sex-
ual transmission of HIV-1 and in the early stages of infec-
tion by HIV-1. Our observations indicate that some
microbicide molecules may be less inhibitory against
CCR5-tropic HIV-1 when the virus is opsonized by com-
plement components, and thus could be less efficient in
early infection of dendritic cells.
In conclusion, virus complement opsonization may
modulate the inhibitory activity of microbicide molecules
against HIV in vitro, and could be also involved in vivo as
possible modulatory factor of their anti-HIV-1-inhibitory
activities when the drugs are mixed with male genital
secretions containing high concentrations of comple-
ment. Microbicide candidate molecules whose in vitro
anti-HIV activity is not influenced, or positively rein-
forced, by complement opsonisation of HIV, could be
likely retained for further steps of preclinical develop-
ment. However, the hypothesis that seminal complement
components could in vivo modulate the inhibitory activi-
ties of several microbicide candidate molecules acting at
different targets against the virus, warrants further inves-
tigations.
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